Another approach uses liquid biopsies to monitor KRAS-mutated chromosomal instability to identify pseudoprogression and quantified circulating tumor DNA (ctDNA) has been shown to decrease in pseudoprogression compared with true progression (4, 20). The gene discussed is KRAS; the disease is neoplasm.